| Document |
Document Title |
|
WO/2024/109840A1 |
The present disclosure relates to a fused ring compound, a conjugate thereof and the use thereof. The compound and the conjugate of the present disclosure have good activity of inhibiting tumor cells, stability, and in-vivo drug efficacy...
|
|
WO/2024/109945A1 |
The present invention pertains to the biomedical field, and particularly relates to a series of selenium containing heterocycle compounds. The present invention also relates to a pharmaceutical composition comprising the compound, and th...
|
|
WO/2023/164612A9 |
Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disea...
|
|
WO/2024/109707A1 |
Provided in the present invention are fused ring pyridone derivatives, a preparation method therefor, and the use thereof. Specifically, provided in the present invention are compounds represented by formula (I), or stereoisomers, tautom...
|
|
WO/2024/112854A1 |
The present disclosure relates to RIPK2 inhibitors represented by structural formula (I). The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflamm...
|
|
WO/2024/069592A8 |
The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a com...
|
|
WO/2024/109949A1 |
A ligand conjugate, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or pharmaceutically acceptable salt or hydrate thereof; same comprises a structure as represented by formula I and mayb be used as an anti-tumor drug.
|
|
WO/2024/108311A1 |
A method of assessing a risk of developing Alzheimer's disease (AD) and of diagnosing AD in a subject comprising: comparing a level of extracellular vesicles (EVs) that are positive for at least one biomarker in a biofluid sample taken f...
|
|
WO/2024/103461A1 |
A lysosome-targeting acid response aggregation-induced luminescent fluorochrome MG-RhA, a method for preparing same, and use thereof, pertaining to the technical field of luminescent materials. The fluorochrome MG-RhA takes rhodamine B a...
|
|
WO/2024/106914A1 |
The present invention relates to heteroayl derivatives and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR and/or HER2, which may be usefully employed as a therapeutic ...
|
|
WO/2024/104425A1 |
The present invention pertains to the technical field of pharmaceuticals and particularly relates to a KRAS inhibitor compound, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention relates to a compo...
|
|
WO/2024/107393A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2024/106261A1 |
This compound, which is represented by the depicted general formula, has excellent light-emitting properties. R1 to R3 and Z represent D or a substituent; R4 to R8 represent H, D, or a substituent; at least one of R1 to R8 represents an ...
|
|
WO/2024/102177A1 |
Disclosed herein are methods of treating brain cancer in a subject, such as glioblastoma, comprising administering inhibitors of synaptic signaling to the subject.
|
|
WO/2024/098735A1 |
The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, and an organic electroluminescent apparatus and an electronic device using same. The organic compound has a struct...
|
|
WO/2024/102625A1 |
In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
|
|
WO/2024/094208A1 |
The present invention relates to a series of cyano-substitute-containing heterocyclic derivatives and a preparation method therefor, and specifically relates to a compound represented by formula (IV), a stereoisomer thereof, and a pharma...
|
|
WO/2024/094575A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2024/098066A1 |
Disclosed herein, in part, are novel exatecan derivatives with novel chemical linkers that include cathepsin B cleavable moieties and conjugated to targeting antibodies. In a preferred embodiment the antibody is an anti-TROP2, an anti-EG...
|
|
WO/2024/094016A1 |
The present invention provides a salt of a dioxane quinoline compound, a crystal form thereof, preparation methods therefor and uses thereof. Specifically, the present invention relates to N-(3-fluoro-4-((5-(3-morpholinopropoxy) -2,3-dih...
|
|
WO/2024/094156A1 |
Provided is a compound represented by formula (I), or a stereoisomer thereof, an optical isomer thereof, a solvate thereof, an isotope derivative thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a ligan...
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/090775A1 |
The present specification provides a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer of an organic light-emitting device.
|
|
WO/2024/091983A1 |
The present invention relates to novel compounds and compositions thereof. The compositions are useful in the treatment of an epithelial or endothelial barrier dysfunction disorder in a subject.
|
|
WO/2024/091538A1 |
The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
|
|
WO/2024/089023A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2024/087977A1 |
The present invention relates to a phenylurea compound capable of targeting SHP2, and a preparation method therefor, the use thereof and a pharmaceutical composition thereof. The compound is as represented by formula (I). The present inv...
|
|
WO/2024/085699A1 |
The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in te...
|
|
WO/2024/083773A1 |
The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythemato...
|
|
WO/2024/086644A1 |
Described herein are compounds or conjugates of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain pr...
|
|
WO/2024/086111A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/086634A1 |
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
|
|
WO/2024/083237A1 |
The disclosure provides substituted heteroaryl bicyclic compounds as represented in Formula I and the use thereof, wherein, A1, A2, B1, B2, B3, ring Z, L, Cy1 and Cy2 are defined herein. The compounds of Formula I can be used to prevent ...
|
|
WO/2024/086744A2 |
Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (I) are as defined in the application. Such compounds can be useful as anti-cancer agents.
|
|
WO/2024/081372A1 |
The present invention relates to processes for the preparation of the compound of formula 1 from the intermediates the intermediates of formulae 8 to 10 in the presence of the cyclisation catalyst CuSO4 Compound 1 is the agent-linker con...
|
|
WO/2024/078569A1 |
The present invention relates to an aromatic amide derivative, a preparation method therefor, and a use of a pharmaceutical composition comprising same in medicine. Specifically, the present invention relates to an aromatic amide derivat...
|
|
WO/2024/081318A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
|
WO/2024/081927A1 |
Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
|
|
WO/2024/078649A1 |
The invention relates to furopyridine compounds of formula (I) for use in the treatment of FLT3-related, DDR-related and MAP4K-related diseases.
|
|
WO/2024/078592A1 |
The present invention relates to a compound targeting fibroblast activation protein (FAP) as shown in formula (X) and a use thereof, and further relates to a pharmaceutical composition containing the compound and a use. The compound or t...
|
|
WO/2024/078449A1 |
The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.
|
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
|
WO/2024/077006A1 |
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2024/075051A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
|
|
WO/2024/075070A2 |
The present invention relates to a compound represented by chemical formula 1 as an SOS1 inhibitor, optical isomers thereof, stereoisomers thereof, solvates thereof, isotopic variants thereof, tautomers thereof, or pharmaceutically accep...
|
|
WO/2024/073475A1 |
Described herein are compounds of Formula II or conjugates of Formula II' and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or degraders for certain p...
|
|
WO/2024/066984A1 |
Provided in the present invention is a tricyclic derivative, and the structure thereof is as shown in formula (I). In addition, further disclosed in the present invention are a pharmaceutically acceptable salt of the derivative, a stereo...
|
